The ALS Society of Manitoba and Amylyx Pharmaceuticals Canada are thrilled to announce Pharmacare to cover ALBRIOZA. It has been added to the Manitoba Pharmacare drug benefit program effective August 24, 2023.
ALBRIOZA is used for the treatment of amyotrophic lateral sclerosis (ALS) and offers those living with ALS the possibility of extending their period of functional independence, granting them invaluable additional time.
“We commend the Government of Manitoba for it’s decision to offer public coverage for this treatment,” said Diana Rasmussen. “As this fatal disease progresses so quickly, access to approved treatment options represents a lifeline of hope and dignity for those battling this devastating disease.”
